National Research Corporation (NRC)
NRC Down 8% Despite Q2 Earnings Rising Y/Y on TRCV Growth
NRC Health's Q2 earnings per share rise year over year on higher recurring contract value and strong Governance Institute bookings, partly offset by elevated operating expenses.
NRC Health (NRC) Q2 2026 Earnings Call Transcript
NRC Health (NRC) Q2 2026 Earnings Call Transcript
National Research Q2 Earnings Call Highlights
National Research NASDAQ: NRC, operating as NRC Health, reported second-quarter results marked by 11% year-over-year growth in total recurring contract value, while management said investments in implementation, customer success and product development supported a large customer deployment and future growth initiatives.
Is NuScale's NRC Licensing Lead Its Biggest Competitive Advantage?
SMR's dual NRC Part 52 approvals give it a licensing head start that could speed deployments for AI sites and industry.
NRC Health (NRC) Q1 2026 Earnings Call Transcript
NRC Health (NRC) Q1 2026 Earnings Call Transcript
NRC Health Surges 62% in a Year: Should You Buy the Stock?
Strong recurring revenues, rising AI adoption and alignment with value-based care trends position NRC to capitalize on growing demand for patient-centric healthcare solutions.
NRC's Q4 Earnings Down Y/Y on High Client Attrition, Stock Falls 27%
NRC Health's Q4 EPS and revenues decline year amid prior client attrition, though recurring contract value grew 8%, pointing to recovery prospects in 2026.
National Research Corporation (NRC) Q4 2025 Earnings Call Prepared Remarks Transcript
National Research Corporation (NRC) Q4 2025 Earnings Call Prepared Remarks Transcript
National Research: The Turnaround Is Invisible Until It Isn't
National Research Corp. is undervalued, trading at a modest multiple despite a clear pivot from contraction to growth. TRCV, NRC's key forward metric, grew 8% YoY, signaling imminent revenue acceleration and a strong 2026 setup. Margins are expanding as cost structure is rationalized; normalized FCF could approach $38M in 2026 after one-off expenses subside.
Nuclear startup that sued NRC raises $130 million with backing from Anduril's Palmer Luckey and senior Palantir executive
Valar Atomics raised $130 million with participation from Anduril Industries founder Palmer Luckey and Palantir Chief Technology Officer Shyam Sankar. Valar is developing reactor technology that uses helium as a coolant and operates at higher temperatures than traditional plants.
NRC Stock Up 12% Despite Q3 Earnings Down Y/Y on Rising Interest Costs
NRC Health's Q3 earnings are impacted by rising interest expenses, but margin gains, cash flow strength and a 33% dividend hike offset these headwinds.
National Research Corporation (NRC) Q3 2025 Earnings Call Prepared Remarks Transcript
National Research Corporation (NASDAQ:NRC ) Q3 2025 Earnings Call October 28, 2025 4:00 PM EDT Company Participants Trent Green - CEO & Director Shane Harrison - Chief Financial Officer Presentation Operator Good afternoon. Thank you for attending the NRC Health Third Quarter 2025 Earnings Call.
